Efficacy and Safety of PD-1/PD-L1 plus CTLA-4 antibodies +/- Other Therapies in Lung Cancer: A Systematic Review and Meta-Analysis

Xiang Shen, Hua Xiao, Shangke Huang, Jiexing Liu, Zhuolan Ran, Bin Xiong

Xiang Shen, Department of Respiratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China, 646000

Hua Xiao, Department of Respiratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China, 646000

Shangke Huang, Oncology Department, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China, 646000

Jiexing Liu, Department of Respiratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China, 646000

Zhuolan Ran, Department of Respiratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China, 646000

Bin Xiong, Department of Respiratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China, 646000

Corresponding author: Correspondence to Dr Bin Xiong; xionbin321@163.com

KEY WORD: PD-1/PD-L1 CTLA-4 Lung cancer Efficacy Safety

WORD NUMBER: 3052

ABSTRACT

Background: Immune checkpoint inhibitors have brought hope for patients with advanced lung cancer, among which PD-1/PD-L1 and CTLA-4 inhibitors have achieved considerable results. This meta-analysis aims to investigate the efficacy and safety of PD-1/PD-L1 combined with CTLA-4 antibodies in patients with advanced lung cancer.

Materials and Methods: Randomized controlled trials (RCTs) study of PD-1/PD-L1 combined with CTLA-4 inhibitors for advanced lung cancer was searched in the database for systematic review and meta-analysis.

Results: The meta-analysis finally included 4 trials (actually 3 trials), and the results showed that the overall response rate of PD-1/PD-L1 combined with CTLA-4 inhibitor was higher than that of the control group (ORR = 2.29 [95% CI 1.58 3.32], $P < 0.0001$). PFS significantly improved compared with conventional treatment (HR = 0.69 [95% CI 0.56, 0.85], $P = 0.0005$), which was statistically significant. OS also improved but did not statistically significant (HR = 0.80 [95% CI 0.61, 1.05], $P = 0.11$). PD-1/PD-L1 combined with CTLA-4 inhibitors had a higher incidence of adverse reactions than conventional treatment (OR = 1.72 [95% CI 0.59, 5.09], $P = 0.33$), but the incidence of grade ≥ 3 AEs was lower than the control group (OR = 0.96 [95% CI 0.64, 1.44], $P = 0.85$).

Conclusion: Double checkpoint inhibitor PD-1/PD-L1 combined with CTLA-4 antibody has synergistic anti-cancer activity and improved ORR and PFS in lung cancer. Adverse reactions are more common than conventional treatment, but are generally controllable. Therefore, PD-1/PD-L1 combined with CTLA-4 inhibitors provides a beacon for the treatment of advanced lung cancer, which has guiding significance for the treatment selection in the future.

Key Words: programmed cell death 1; programmed cell death-ligand 1; Cytotoxic T lymphocyte antigen-4; overall survival; progression-free survival; meta-analysis

Introduction

Although undergoing smoking cessation, early screening and treatment have reduced lung cancer mortality,¹ it still remains the most deadly cancer among cancer patients. Because lung cancer in the early stages is usually asymptomatic or has only cough and sputum without attention, most patients are diagnosed in the middle-late stages and haven't opportunity for surgery. It analysed the 5-year survival rate of patients with stage IV is only 4% in the Cancer (2019).² Even with the presence of treatable gene mutations, using targeted drugs will eventually activate acquired resistance mutations or compensatory pathways,³ leading to disease progression occurring 8-19 months after starting treatment.^{4 5} We need to actively find other therapies to solve this dilemma.

Studies have found that cancer cells in the context of the tumor microenvironment (TME) through regulatory T cells (Tregs) change immune homeostasis, suppress the activation and effector functions of innate and acquired immune systems, thereby escape immune surveillance.^{6 7} When PD-1 is combined with PD-L1, it inhibits the proliferation and survival of CD8 + toxic T cells;⁸ at the same time, changes T cell differentiation, impairs the differentiation of effector T cells (Teff) and memory T cells (Tm), up-regulates regulatory T lymphocytes (Treg) and depleted T cells (Tex), thus suppress T-cell immune effects. CTLA-4 has greater affinity than CD28 for binding to CD80 and CD86 on antigen-presenting cells, reducing the synergistic stimulation of the T cell receptor signal,⁹ thereby inhibiting CD28-B7-1/2 costimulation, leading to T cell dysfunction and apoptosis.¹⁰ This is the escape of adaptive immunity to endogenous anti-tumor mechanisms.¹¹ Immune checkpoint inhibitors (ICIs) restore and maintain the function of the immune system against tumor cells by blocking specific signaling pathways, in which cytotoxic T cells play a important role in immune monitoring and anti-tumor responses.¹² Compared with chemotherapy, PD-1/PD-L1 and CTLA-4 inhibitors have higher objective response rate or longer overall survival and better toxicity profile.^{13 14} In particular, patients without targeted cancer mutation genes receiving tumor

immunotherapy is improved the long-term survival rate,^{15 16} and it is a new treatment standard for patients with advanced non-small cell lung cancer with new diagnosis, general conditions, and no contraindications.¹⁷

However, mono-immunotherapy significantly prolonged survival in patients with high PD-L1,¹⁸ which is only beneficial to a small number of patients.¹⁹ Greater therapeutic effectiveness can be achieved at the cost of corresponding side effects through synergistic or combined treatment. Recent clinical trials have demonstrated that the dual checkpoint inhibitors Ipilimumab plus Nivolumab can synergistically enhance T cell functions and the immune system's ability to fight tumor cells through different and complementary mechanisms,²⁰ have a better curative effect than Nivolumab monotherapy. The effect was better in patients with high PD-L1,²¹ and reducing the proportion of patients with advanced tumors.²²

Immune-related adverse events (irAEs), which are different from chemotherapy-related toxic reactions,²³ are up-regulated immune systems leading to severe inflammatory reactions and immune toxicity.²⁴ The mechanism may be related to Tregs. Tregs are one of the most abundant suppressor cells in the TME, and express a large number of checkpoint molecules such as CTLA-4 and PD-1, to maintain immune homeostasis and avoiding autoimmunity. Therefore, the targeting effect of ICIs on Tregs may lead to the occurrence of irAEs.²⁵ These events are usually controllable²⁶ and can be effectively controlled and managed by immunosuppressive methods such as steroids.²⁷ However, there are still a few patients happen serious adverse reactions, with the highest mortality caused by neurological and cardiac toxicity.²⁸

Several clinical trials have been conducted to evaluate the efficacy and toxicity of PD-1/PD-L1 combined with CTLA-4 antibodies in patients with advanced lung cancer, but the results such as progression-free survival (PFS) and overall survival(OS) are controversial. Therefore, we conducted a systematic meta-analysis using data from published literature to make a systematic review and meta-analysis on the efficacy and safety of PD-1/PD-L1 combined with CTLA-4 antibody and/or other therapeutic regimens in lung cancer.

Materials and methods

We follow principle in this systematic review and meta-analysis study is the system review and meta-analysis (PRISMA) guidelines for priority reporting projects.

Systematic Review and Meta-Analysis of All RCTs Testing the PD-1/PD-L1 plus CTLA-4 antibodies +/- Other Therapies in lung cancer

Data sources and search strategy

We searched PubMed, Web of Science, the Cochrane Library, Ovid, Embase for RCTs testing the PD-1/PD-L1 plus CTLA-4 antibodies in patients with lung cancer, without any language or date restrictions. The following retrieval strategy was employed: (((PD-1 OR PD-L1 OR Pembrolizumab OR Nivolumab OR Cemiplimab-rwlc OR Toripalimab OR Sintilimab OR Atezolizumab OR Avelumab OR Durvalumab) AND (CTLA-4 OR Ipilimumab OR Tremelimumab)) AND lung cancer) AND trial). And manual searches were performed for references that met the inclusion criteria to avoid missing any studies.

Inclusion and exclusion criteria

Inclusion and exclusion criteria were independently evaluated by two researchers based on the PICO principle. The included studies must meet the following criteria: (1) studies published in English; (2) randomized controlled clinical trials to study the efficacy and safety of (PD-1 OR PD-L1 OR Pembrolizumab OR Nivolumab OR Cemiplimab-rwlc OR Toripalimab OR Sintilimab OR Atezolizumab OR Avelumab OR Durvalumab) AND (CTLA-4 OR Ipilimumab OR Tremelimumab); (3) the patients were histologically diagnosed with lung cancer, not including HIV, organ transplantation, viral infection and other special patients; (4) analysis related data of objective response rate (ORR), progression free survival (PFS), overall survival (OS), and toxicity. The following studies were excluded: (1) reviews, editorials, case reports, or animal and cellular studies; (2) incomplete required data; (3) no dose and usage.

Data extraction and quality assessment

Two researchers independently conducted the study selection process based on the inclusion and exclusion criteria, and extracted the following information: first author name, publication year, trial phase, clinical trial number, trial design, pathological type, sample size, usage and dosage, follow-up time, median OS and PFS, irAEs. If there are disagreements in the studies selection and data extraction process, reach a consensus through discussion or when necessary consult the third investigator.

We used the reporting method of Jadad et al²⁹ to evaluate the quality of the included studies.

Data synthesis and statistical analysis

We used Review Manager 5.3 for statistical analysis. The Q test and I^2 statistics were evaluated the statistical heterogeneity. When $P < 0.05$ or $I^2 > 50\%$, heterogeneity is indicated statistically significant, and performed using random effects models, otherwise performed using fixed effect model. $HRs > 1$ of OS and PFS was beneficial to the control group, while $HRs < 1$ was beneficial to the PD-1/PD-L1 combined CTLA-4 antibody group. $ORs > 1$ of ORR and AEs means higher effective rate and toxicity, while $ORs < 1$ have lower effective rate and safety. $P < 0.05$ was considered statistically significant, and all P values were bilateral.

Results

Study characteristics and risk of bias

Figure 1 shows a flow chart containing the study. A preliminary literature search screened a total of 3983 records from the database; 3317 of them were after deleting duplicate records; 86 were after screening; 43 were after screening titles and abstracts; 3 studies After reviewing each publication. All relevant references have been reviewed. Finally, three randomized controlled trials were included in this meta-analysis (one of the trials had two trials to compare the efficacy and toxicity with the control group, which were conducted as two independent trials), all using the response evaluation standard (RECIST) or WHO standards. All trials are randomized,

Table I

	name of trail	histology	experiment						control						HR for OS	HR for PFS
			drug	number	ORR	Median OS (95% CI)	Median PFS(95% CI)	Grade 3-4 AES	drug	number	ORR	Median OS (95% CI)	Median PFS(95% CI)	Grade 3-4 AES		
Kowalski, D.M. 2018	ARCTIC(NCT 02352948) phase 3	NSCLC	Durvalumab 20mg/kg +Tremelimumab 1mg/kg i.v. q4w	176	26	11.5months	3.5months	46.8%	erlotinib 150mg qd po + gemcitabine 1000mg/m ² i.v.	117	8	8.7months	3.5months	54.5%	0.8(0.61,1. 05)	0.77(0.59,1 .01)
M.D.Hellm ann 2018	Checkmate227 (NCT024778 26) phase 1	NSCLC	nivolumab 3mg/kg q2w + ipilimumab 1mg/kg q6w	139	63	-	4.9months(4. 1-5.6)	31.2%	platinum-based chemotherapy	160	43	-	5.5months(4. 6-5.6)	36.1%		0.58(0.41,0 .81)
Scott J Antonia(1) 2016	Checkmate032 (NCT019283 94) phase 1/2	SCLC	nivolumab 1mg/kg+ipilimuma b 3mg/kg q3w	61	14	7.7(3.6-18) months	2.6(1.4-4.1)m onths	30%	nivolumab 3mg/kg	49	5	4.4(3.0-9.3)months	1.4(1.4-1.9) months	13%		
Scott J Antonia(2) 2016	Checkmate032 (NCT019283 94) phase 1/2	SCLC	nivolumab 3mg/kg+ipilimuma b 1mg/kg, q3w	54	10	6.0(3.6-11. 0)months	1.4(1.3-2.2)m onths	19%	nivolumab 3mg/kg	49	5	4.4(3.0-9.3)months	1.4(1.4-1.9) months	13%		

controlled, open-label clinical trials. These included 430 experimental groups and 375control groups,³⁰⁻³² which mainly studied Ipilimumab + Nivolumab and Durvalumab + Tremelimumab for the treatment of lung cancer. Table I summarizes the detailed characteristics of the included studies.

We assessed the quality of each study in this analysis based on the Jadad score, and Table II provides the risk results of the bias assessment.

Table II Risk of Bias

	random sequence generation (selection bias)	allocation concealment (selection bias)	blinding of participants and personnel (performance bias)	blinding of outcome assessment (detection bias)	incomplete outcome data (attrition bias)	selective reporting (reporting bias)	other bias
KowalskiD.M. 2018	-	?	-	?	-	?	+
M.D.Hellmann 2018	-	?	-	?	-	?	+
Scott J Antonia(1)2016	-	?	-	?	+	?	+
Scott J Antonia(2) 2016	-	?	-	?	+	?	+

Overall response rate (ORR)

Finally, 4 studies conducted in 430 experimental arm patients and 375 control arm patients met the inclusion criteria and were included in the ORR analysis. The ORR funnel plot did not show significant asymmetry (Figure 3), and heterogeneity between studies was not significant ($P = 0.99$, $I^2 = 0\%$). The pooled OR for ORR was performed fixed effect model. This meta-analysis showed that ORR was significantly improved in the treatment of PD-1/PD-L1 combined with CTLA-4 antibody (OR=2.29[95%CI 1.58, 3.32], $P < 0.0001$) (Figure 2), which was statistically significant. The clinical efficacy of PD-1/PD-L1 combined with CTLA-4 antibodies in patients with advanced lung cancer is higher than that in the control group. Regardless of whether it is NSCLC or SCLC, the results show that dual ICI therapies improves ORR.

progression-free survival (PFS)

Two trials were included for PFS evaluation. The funnel plot of PFS did not show significant asymmetry, and heterogeneity among studies was not significant ($P = 0.19$, $I^2 = 42\%$). The pooled HR for PFS was performed fixed effect model. In the treatment of lung cancer with PD-1/PD-L1 combined with CTLA-4 antibodies, the HR of PFS improved statistically (HR = 0.69 [95% CI 0.56, 0.85], $P = 0.0005$) (Figure 4).

overall survival (OS)

Only one trial reported OS combined HRs and 95% CI, and heterogeneity could not be evaluated. The results showed that the OS of PD-1/ PD-L1 combined with CTLA-4 antibody was improved but not statistically significant (HR = 0.80[95% CI 0.61, 1.05], $P = 0.11$) (Figure 5).

Immune-related adverse events (irAEs)

Data from AEs were found in 3 studies with significant heterogeneity ($P = 0.0002$, $I^2 = 89\%$). The pooled OR for AEs was performed random effect model. The incidence of AEs was higher than the control group (OR = 1.72 [95% CI 0.59, 5.09], $P = 0.33$) (Figure 6), and fatigue was the most common. There are 4 studies with data from severe AEs (Grade ≥ 3) and heterogeneity ($P = 0.1$, $I^2 = 52\%$). The pooled OR

for AEs (Grade $\geq$ 3) was performed random effect model. The incidence of AEs (Grade $\geq$ 3) was lower than the control group (OR = 0.96[95%CI 0.64, 1.44], P = 0.85) (Figure 7), but it was not obvious. Among them, rash and diarrhea were the most common, anemia and neutrophilic granulocyte counts were most common during chemotherapy.

Discussion

Most lung cancer patients receive chemotherapy and/or radiation therapy,² which have poor antitumor effects. In recent years, some clinical trials have achieved satisfactory results in the treatment of lung cancer with PD-1/PD-L1 and CTLA-4 antibodies, of which Pembrolizumab and Nivolumab can prolong survival for patients with advanced NSCLC,^{33 34} Durvalumab combined with chemotherapy can effectively improve the prognosis of patients with ES-SCLC.³⁵ This meta-analysis investigates the efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors for lung patients.

Nivolumab and Pembrolizumab mainly act on activated T cells in peripheral blood or tumors. By blocking the binding of PD-1 and PD-L1, they cancel the apoptosis of T cells and enable their normal activation and proliferation. Ipilimumab mainly acts on lymph nodes, by blocking the binding of the domain of CTLA-4 to its ligand, activate, proliferate and infiltrate T lymphocytes, and increase the level of active T cells in peripheral blood.³⁶ However, less than 10% of CD8+ T cells in tumors have the ability to recognize cancer cells,³⁷ and the anticancer effect may be caused by T cells entering the tumor from peripheral blood after treatment.³⁸ Therefore, it is particularly important to increase the number of T cells and enhance the effector function through different mechanisms by combining PD-1/PD-L1 and CTLA-4 inhibitors. The combined blocking of CTLA-4 and PD-1/PD-L1 pathways increases the ratio of T_{eff} to Tregs and myeloid-derived suppressor cells (MDSC, which significantly suppresses the ability of cells to respond), thereby reducing immunosuppression and promoting inflammation in the tumor microenvironment.³⁹ At the same time, anti-CTLA-4 antibodies have antibody-dependent cell-mediated cytotoxicity, reduce the negative effect of PD-1 antibodies on activating Tregs; CTLA-4 antibodies lead to compensatory

overexpression of tumor PD-L1, and PD-1 antibodies block the binding of PD-L1 to PD-1; CTLA-4 antibodies increase activated T cells and Tm in peripheral blood, and PD-1 antibodies relieve the inhibition of T cell anti-cancer activity by tumors. Our results reveal the significant effect of dual checkpoint inhibitors treat for advanced lung cancer, with significant improvements in ORR (OR=2.29[95%CI 1.58, 3.32], $P<0.0001$) and PFS (HR = 0.69 [95% CI 0.56, 0.85], $P = 0.0005$); OS also improves (HR = 0.80[95% CI 0.61, 1.05], $P = 0.11$), but no statistical significance.

Can we combine immunosuppressants with other treatments for lung cancer? By activating aKT, cisplatin rapidly increases the expression of PD-L1 in the tumor microenvironment in a dose-dependent manner, increases the clinical efficacy of immunotherapy,^{40 41} and does not affect the immune background of NSCLC after induction, and does not significantly damage antitumor Immune,⁴² but may not persistently. Radiotherapy can restore the recruitment of Th1 lymphocytes in the tumor microenvironment,⁴³ stimulate antigen presentation, increase tumor antigenicity,⁴⁴ form an "immune center", promote tumor immune response.^{45 46} Through more effective control of the immune system, local therapy is converted into systemic therapy, which makes it have synergistic and more effective activity on tumor cells.⁴⁷ Regarding when to use combination therapy, a meta-analysis by Zhou et.al suggests patients with large tumor volume should be treated with immunity combined with other therapies to produce deeper and long-term efficacy, while patients with low tumor volume or extremely high PD-L1 TPS should be treated with immunomonootherapy.⁴⁸ which requires more clinical trials validation.

In order to expand the population benefiting from immunotherapy, detection of biomarkers before treatment is necessary. In the Checkmate 568 study, patients with stage IIIB/IV NSCLC received Nivolumab and Ipilimumab. The ORs of patients with PD-L1 expression $< 1\%$ and $\geq 1\%$ were 14.9%[95% CI 8.9, 22.8], 41.3%[95% CI 33,50], respectively, MPFS is 2.8months[95% CI 2.1,4.0], 6.8months[95% CI 4.0, 11.3], and the OR of patients with PD-L1 $\geq 50\%$ is 50%[95% CI 37.6, 62.4].⁴⁹ It is suggested that tumor PD-L1 expression is significantly enhanced when receiving dual immunosuppressants at 1% or higher, which has been considered to a predictive

biomarker of immune checkpoint inhibitor response.⁵⁰ However, PD-L1 expression is heterogeneous and is affected by chemotherapy and targeted therapy.⁵¹ The immune response to anti-CTLA-4 or anti-PD-1/CTLA-4 combination therapy in high TMB tumors may not depend on PD-L1 expression.⁵² Several studies have shown a correlation between TMB and the benefits of ICIs in NSCLC, SCLC, and melanoma.⁵³ The higher the TMB, the more mutations in the tumor genome, the higher the probability of new antigens appearing on the tumor surface, the stronger the immunogenicity, making the tumor more easily recognized by T cells;⁵⁴ and it is significantly related to the response of immunotherapy.⁵⁵ Hellmann et al. according to TMB quantitative classification: low (0 to <143 mutations), medium (143 to 247 mutations) and high (≥ 248 mutations), the ORR of Nivolumab+ipilimumab in SCLC is 22.2%, 16.0%, 46.2%, MPFS is 1.5 months[95% CI 1.3, 2.7], 1.3 months[95% CI 1.2, 2.1], 7.8 months[95%CI 1.8, 10.7], MOS is 3.4 months[95% CI 2.8,7.3], 3.6 months[95% CI 1.8,7.7], 22.0 months[95% CI 8.2, NR], suggesting that dual immunosuppressants have better therapeutic effect and larger clinical value in patients with high tumor mutation load.⁵⁶ The expression of PD-L1 and TMB can be used as predictors of immunotherapy.

The related adverse reactions of PD-1/PD-L1 combined with CTLA-4 inhibitors cannot be ignored. The risk of irAEs in patients treated with CTLA-4 is dose-related,⁵⁷ most grade 3 or higher irAES occurs within 8-12 weeks after starting treatment; PD-1 antibody-related irAEs are relatively low in frequency, most irAEs occur within the first 6 months of treatment and take longer than treatment of CTLA-4 related toxicity.⁵⁸ The organ involvement spectrum of the two is also different, anti-PD-1 drugs cause arthritis more frequently, and anti-CTLA-4 drugs are more related to colitis.⁵⁹ Combining anti-CTLA-4 antibodies and anti-PD-1 antibodies can increase the incidence and severity of irAEs and occur earlier.⁶⁰ This is consistent with our research finding. A big data analysis showed that the risk of immune events is associated with TMB. Cancers with high TMB, such as NSCLC, are associated with higher irAEs during anti-PD-1 therapy.⁶¹ Receiving low-dose glucocorticoids does not inhibit the immune response caused by ICIS, and can continue and maintain a beneficial response

to ICIs.⁵⁹ The combination of anti-PD-1 antibodies and immune antibodies of selectively target specific inflammatory mediators can prevent or delay the progression of advanced tumors with autoimmune diseases without affecting the anti-tumor effect of anti-PD-1 antibodies.⁶² It was observed that even if patients receiving PD-1 antibodies stopped treatment due to the reaction, they could have a longer duration of action without the need to rush to the next treatment.⁶³ However, long-term exposure to immunosuppressants can lead to rare fatal immune-related events.^{64 65}

In our meta-analysis, we included 4 randomized controlled clinical trials, the results showed that the combination of PD-1/PD-L1 and CTLA-4 antibody was effective for the treatment of lung cancer and the occurrence of adverse reactions is controllable. It provides a good option for the treatment of SCLC. A non-randomized controlled trial of Ipilimumab and Nivolumab given postoperatively to patients with ES-SCLC was better than the control group compared with OS-1 year.⁶⁶ Contrary to our findings, more randomized, multicenter, and large sample studies are needed to confirm and evaluate the cost of treatment strategies and patients' quality of life. Our research also has certain limitations that may affect the final results. First, most studies have a small sample size, and currently there are very few data on dual-immune checkpoint inhibitor combination therapy, and fewer studies involving randomized or blinded methods. Second, we extracted trial data from published articles but did not have the patient's original data, which could lead to biases in data analysis. Therefore, more large-scale clinical trials are needed to further verify the effectiveness and safety of dual immunosuppressive antitumor therapy. Multiple RCTs are currently underway to compare the efficacy of PD-1/PD-L1 in combination with CTLA-4 inhibitors and/or other treatment options for advanced cancer, Durvalumab + Tremelimumab (MYSTIC/NCT02453282,⁶⁷ ADRIATIC/NCT03703297,⁶⁸ NEPTUNE/NCT02542293⁶⁹), Durvalumab + Tremelimumab + Chemotherapy (POSEIDON/NCT03164616,⁷⁰ CASPIAN/NCT03043872⁷¹), Nivolumab + Ipilimumab (CheckMate227/NCT02477826,⁷² CheckMate816/NCT02998528⁷³), Pembrolizumab

+ Ipilimumab (KEYNOTE-598/NCT03302234⁷⁴). It is necessary to pay close attention to the test results, perform update analysis, and conduct long-term follow-up.

In conclusion, PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors can improve ORR and PFS in patients with advanced or metastatic lung cancer, but the incidence of adverse reactions is high and generally tolerable. The survival of SCLC is shorter than that of NSCLC,² and treatment is limited. Dual immunosuppressants also have therapeutic effects in SCLC. Despite some limitations, our research indicates that the current PD-1/PD-L1 plus CTLA-4 inhibitors may be a promising treatment strategy for patients with advanced lung cancer, but attention should be paid to the occurrence of adverse reactions.

REFERENCE

1. Jiemin M, Ahmedin J, Stacey AF, et al. The American Cancer Society 2035 challenge goal on cancer mortality reduction. *CA Cancer J Clin* 2019;69:351-62 doi:10.3322/caac.21564 [Published Online First: 08 May 2019].
2. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. *CA Cancer J Clin* 2019;69:363-85 doi:10.3322/caac.21565 [Published Online First: 11 June 2019].
3. Palakurthi S, Kuraguchi M, Zacharek SJ, et al. The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity. *Cancer Immunol Res* 2019;7:1457-71 doi:10.1158/2326-6066.cir-18-0595.
4. Girard N. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? *Future Oncol* Published Online First: 16 Jan 2018 doi:10.2217/fon-2017-0636.
5. Morris TA, Khoo C, Solomon BJ. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors. *Drugs* 2019;79:1277-86 doi:10.1007/s40265-019-01164-3 [Published Online First: 16 July 2019].
6. Najafi M, Farhood B, Mortezaee K. Contribution of regulatory T cells to cancer: a review. *J Cell Physiol* 2019;234:7983–7993 doi:10.1002/jcp.27553 [Published Online

First: 14 Oct 2018].

7. Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. *Semin Cancer Biol* 2015;35(Suppl):S185–98 doi:10.1016/j.semcancer.2015.03.004.
8. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. *Science* 2015;348:69-74 doi:10.1126/science.aaa4971 [Published Online First: 03 Apr 2015].
9. Barber D.L, Wherry E.J, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature* 2006;439:682–7 doi:10.1038/nature04444 [Published Online First: 28 Dec 2015].
10. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. *Cancer Cell* 2015;27:450–61 doi:10.1016/j.ccell.2015.03.001.
11. Paulsen EE, Kilvaer TK, Rakaee M, et al. CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. *Cancer Immunol Immunother* 2017;66:1449-61 doi:10.1007/s00262-017-2039-2.
12. Kim DH, Kim H, Choi YJ, et al. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. *Exp Mol Med* 2019;51:94 doi:10.1038/s12276-019-0295-2 [Published Online First:09 August 2019].
13. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, openlabel, multicentre randomised controlled trial. *Lancet* 2017;389:255–65 doi:10.1016/s0140-6736(16)32517-x [Published Online First:12 Dec 2016].
14. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2016;387:1540–50 doi:10.1016/s0140-6736(15)01281-7 [Published Online First: 19 Dec 2015].
15. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018; 30:863-70 doi:10.1093/annonc/mdy474.

16. Schuler M, Paz-Ares L, Sequist LV, et al. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. *Lung Cancer* 2019;133:10-19 doi:10.1016/j.lungcan.2019.04.006.
17. Ackermann CJ, Reck M, Paz-Ares L, et al. First-line immune checkpoint blockade for advanced Non-Small-Cell Lung Cancer: travelling at the speed of light. *Lung Cancer* 2019;134:245-53 doi:10.1016/j.lungcan.2019.06.007
18. Proto C, Ferrara R, Signorelli D, et al. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): What to add and what to leave out. *Cancer Treat Rev* 2019;75:39-51 doi:10.1016/j.ctrv.2019.03.004
19. Verma V, Sharma G, Singh A. Immunotherapy in extensive small cell lung cancer. *Exp Hematol Oncol* 2019;8:5 doi:10.1186/s40164-019-0129-x [Published Online First: 04 Feb 2019].
20. Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. *Ann Oncol* 2018;29(suppl 10):abstract LBA6.
21. Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. *Lancet Oncol* 2017;18:31-41 doi:10.1016/S1470-2045(16)30624-6 [Published Online First: 05 Dec 2016].
22. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med* 2015;373:1270–1 doi:10.1056/nejmc1509660 [Published Online First: 24 Sep 2015].
23. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med* 2018;378:158-68 doi:10.1056/nejmra1703481 [Published Online First: 11 Jan 2018].
24. Naqash AR, Appah E, Yang LV, et al. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. *J Immunother Cancer* 2019;7:169 doi:10.1186/s40425-019-0648-3 [Published Online First: 05 July 2019].
25. Alissafi T, Hatzioannou A, Legaki AI, et al. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells. *J*

Autoimmun 2019;104:102310 doi:10.1016/j.jaut.2019.102310

26. Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. *Immunotargets Ther* 2017;6:51-71 doi: 10.2147/itt.s141577 [Published Online First:24 Aug 2017]

27. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2018; 36:1714-68 doi:10.1200/jco.2017.77.6385 [Published Online First:14 Feb 2018].

28. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. *Ann Oncol* 2016;27:559-74 doi:10.1093/annonc/mdv623

29. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;17:1-12

30. Kowalski DM, Reinmuth N, Orlov SV, et al. ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥ 3 L advanced NSCLC treatment. *Ann Oncol* 2018;29(suppl 8):abstract 1378O.

31. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. *N Engl J Med* 2018;378:2093-04 doi:10.1056/nejmoa1801946 [Published Online First:31 May 2018].

32. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncol* 2016;17:883-95 doi:10.1016/S1470-2045(16)30098-5 [Published Online First:04 June 2016].

33. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2016;387:1540-1550 doi:10.1016/S0140-6736(15)01281-7 [Published Online First:19 Dec 2015].

34. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med* 2015;373:1627-1639 doi:10.1056/NEJMoa1507643 [Published Online First:22 Oct 2015].
35. Paz-Ares L, Dvorkin M, Chen YB, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *Lancet* 2019;394:1929-39 doi:10.1016/S0140-6736(19)32222-6 [Published Online First:23 Nov 2019].
36. Robert L, Tsoi J, Wang X, et al. CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire. *Clin Cancer Res* 2014;20: 2424–32 doi:10.1158/1078-0432.ccr-13-2648
37. Scheper W, Kelderman S, Fanchi LF, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. *Nat Med* 2018;25:89-94 doi:10.1038/s41591-018-0266-5 [Published Online First:03 Dec 2018].
38. Li JY, Byrne KT, Yan FX, et al. Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. *Immunity* 2018;49:178–193.e7 doi:10.1016/j.immuni.2018.06.006 [Published Online First:26 June 2018].
39. Chae YK, Arya A, Iams W, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). *J Immunother Cancer* 2018;6:39 doi: 10.1186/s40425-018-0349-3.
40. Tran L, Allen CT, Xiao R, et al. Cisplatin Alters Antitumor Immunity and Synergizes with PD1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma. *Cancer Immunol Res* 2017;5:1141–51 doi:10.1158/2326-6066.CIR-17-0235
41. Fournel L, Wu Z, Stadler N, et al. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. *Cancer Lett* 2019;464:5-14 doi:10.1016/j.canlet.2019.08.005
42. Remark R, Lupo A, Alifano M, et al. Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer

- patients. *Oncoimmunology* 2016;5:e1255394 doi:10.1080/2162402X.2016.1255394 [Published Online First:18 Dec 2016].
43. Durante M, Reppingen N, Held KD. Immunologically augmented cancer treatment using modern radiotherapy. *Trends Mol Med* 2013;19:565–82 doi:10.1016/j.molmed.2013.05.007 [Published Online First:09 July 2013].
44. Bos PD, Plitas G, Rudra D, et al. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. *J Exp Med* 2013;210:2435–66 doi:10.1084/jem.20130762 [Published Online First:14 Oct 2013].
45. Gupta A, Probst HC, Vuong V, et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. *J Immunol* 2012;189:558–66. doi:10.4049/jimmunol.1200563 [Published Online First:15 July 2012]
46. Demaria S, Bhardwaj N, McBride W.H, et al. Combining radiotherapy and immunotherapy: a revived partnership. *Int J Radiat Oncol Biol Phys* 2005;63:655–66 doi: 10.1016/j.ijrobp.2005.06.032 [Published Online First:01 Nov 2005]
47. De WK, Vermaelen K, De MG, et al. The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. *Oncoimmunology* 2015;4:e1042198 doi: 10.1080/2162402X.2015.1042198 [Published Online First:27 May 2015].
48. Buttiglierio C, Allis S, Tucci M, et el. Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. *Cancer Treat Rev* 2018;69:215–23 doi:10.1016/j.ctrv.2018.07.010
49. Ready N, Hellmann MD, Awad MM, et al. First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. *J Clin Oncol* 2019;37:992–1000 doi:10.1200/JCO.18.01042 [Published Online First:20 Feb 2019].
50. Yu H, Boyle TA, Zhou C, et al. PD-L1 Expression in Lung Cancer. *J Thorac Oncol* 2016;11:964–975 doi:10.1016/j.jtho.2016.04.014
51. Chan TA, Yarchoan M, Jaffee E, et al. Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic. *Ann Oncol* 2018;30:44–56 doi:10.1093/annonc/mdy495 [Published Online First:05 Nov 2018].

52. Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. *Cell* 2016;165:35-44 doi:10.1016/j.cell.2016.02.065 [Published Online First:24 Mar 2016].
53. Hellmann MD, Nathanson T, Rizvi H, et al. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. *Cancer Cell* 2018;33:843-852.e4 doi:10.1016/j.ccell.2018.03.018 [Published Online First:12 Apr 2018].
54. Riaz N, Morris L, Havel JJ, et al. The role of neoantigens in response to immune checkpoint blockade. *Int Immunol* 2016;28:411–9 doi:10.1093/intimm/dxw019.
55. Forschner A, Battke F, Hadaschik D, et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study. *J Immunother Cancer* 2019;7:180 doi:10.1186/s40425-019-0659-0 [Published Online First: 12 July 2019].
56. Hellmann MD, Margaret KC, Mark MA, et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. *Cancer Cell* 2018;33:853 doi:10.1016/j.ccell.2018.04.001 [Published Online First:14 May 2018].
57. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. *N Engl J Med* 2016;375:1845–55 : doi:10.1056/NEJMoa1611299 [Published Online First:10 Nov 2016].
58. Martins F, Sofiya L, Sykietis GP, et al. Adverse effects of immune-checkpoint inhibitors:epidemiology,management and surveillance. *Nat Rev Clin Oncol* 2019;16:563-80 doi:10.1038/s41571-019-0218-0 [Published Online First:15 May 2019].
59. Buckley LM, Suarez-Almazor ME. Is Immune Check Point Inhibitor Treatment an Option for Patients with Rheumatic Diseases and Cancer? *Arthritis Rheumatol* 2019;71:1971-73 doi:10.1002/art.41064
60. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *N Engl J Med* 2015;372:2006–17 doi: 10.1056/NEJMoa1414428 [Published Online First:]

61. Bomze D, Hasan Ali O, Bate A, et al. Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden. *JAMA Oncol* 2019;5:1633-1635 doi:10.1001/jamaoncol.2019.3221 22 [Published Online First:Aug 2019].
62. Uemura M, Trinh VA, Haymaker C, et al. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. *J Hematol Oncol* 2016;9:81 doi:10.1186/s13045-016-0309-7
63. Iivanainen S, Koivunen JP. Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients. *Oncology* Published Online First:31 Oct 2018 doi: 10.1159/000493193.
64. Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. *JAMA Oncol* 2018;4:1721-8 doi:10.1001/jamaoncol.2018.3923 [Published Online First:13 Sep 2018]
65. Haanen JBAG, Carbone F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and followup. *Ann Oncol* 2018;29(suppl 4): iv264-iv266 doi:10.1093/annonc/mdy162.
66. Perez BA, Kim S, Dilling TJ, et al. A Prospective Single Arm Phase I/II Study: Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy for Patients with Extensive-Stage Small Cell Lung. *Int J Radiat Oncol Biol Phys* 2019;105: S36 doi:10.1016/j.ijrobp.2019.06.452 [Published Online First:1 sep 2019].
67. Von Pawel J, Fischer J, Alt J, et al. MYSTIC - A Phase III, randomized, open-label study of Durvalumab (MEDI4736) in combination with Tremelimumab or Durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced stage IV non small cell lung cancer (aNSCLC): A German update. *Oncol Res Treat* 2016;39:87.

68. Senan S, Shire N, Mak G, et al. ADRIATIC: A phase III trial of durvalumab 6 tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer. *Ann Oncol* 2019;30:25.
69. Mok T, Schmid P, De Castro G, et al. First-line durvalumab plus tremelimumab vs platinum-based chemotherapy for advanced/metastatic NSCLC: Phase 3 NEPTUNE Study. *J Thorac Oncol* 2017;12:S1084.
70. Thomas M, Grohe C, Eberhardt W, et al. POSEIDON: A phase 3 study of first-line Durvalumab ± Tremelimumab + chemotherapy vs chemotherapy alone in metastatic NSCLC. *Oncol Res Treat* 2018;41:295.
71. Paz-Ares L, Jiang H, Huang Y, et al. Caspian: Phase 3 study of first-line durvalumab ± tremelimumab + platinum-based chemotherapy vs chemotherapy alone in ED-SCLC. *J Thorac Oncol* 2017;12:S2398.
72. Paz-Ares L, Brahmer J, Hellmann MD. CheckMate 227: A randomized, open-label phase 3 trial of nivolumab nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC). *Ann Oncol* 2017;28.
73. Felip E, Brahmer J, Broderick S, et al. CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC. *J Thorac Oncol* 2018;13:S831-S832
doi:10.1016/j.jtho.2018.08.1478
74. Boyer M, McLean J, Xu L, et al. Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598. *J Thorac Oncol* 2018;13:S462 doi:10.1016/j.jtho.2018.08.565.

Footnotes

Contributors: XS and HX: conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article, final approval; JL and ZR: acquisition of data, analysis and interpretation of data, drafting the article, final

approval; SH: interpretation of data, revising the article, final approval; BX: interpretation of data, revising the article, critical revision, final approval.

Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: None declared.

Patient consent for publication: Not required.

Provenance and peer review: Not commissioned; externally peer reviewed.

Data availability statement: No data are available.